Yes. I believe if Avant could get $40 million up front for CDX 110, PPHM can get more than that for Cotara GBM. Final Indian Phase II GBM data will all be in by this fall and Mary Boyd should have the Cotara license closed by Christmas.
Having $40 million in the bank from a Cotara license is more than enough to bring Ph II Bavi data to the point where first mega license can be closed.
Note that Cotara has these four advantages over CDX 110:
1. Cotara is effective on 100% of GBM tumor types whereas CDX-110 is effective on only the 45% of GBM tumors that show the EGFRvlll marker.
2. Cotara involves a single infusion, whereas CDX-110 is only effective when combined with a 3-week continuous daily Temozolomide dosing regimen.
3. Cotara enables patients to avoid the side effects of chemotherapy.
4. Cotara can be used synergistically with CDX-110 as an additive therapy to achieve complete remissions because any therapy like CDX plus TMZ that causes necrosis creates more target for Cotara and causes Cotara to work even better.
Perhaps these are the same four reasons why Avant pps has fallen so much in last few weeks.
News 
Market Data 
Discover 
